Medicamen Biotech Share Price | Medicamen Biotech Stock Screener
MEDICAMEQ
Pharmaceuticals
Share Price NSE
₹241.85
▲
4.20 (1.77%)
Share Price BSE
₹242.20
▲
3.90 (1.64%)
As of July 24, 2026, the Medicamen Biotech share price (NSE: MEDICAMEQ) is ₹241.85 on NSE and ₹242.20 on BSE, up 1.77% from the previous close, with shares trading between ₹233.20 and ₹243.00, and a 52-week range of ₹223.30–₹415.95.
Analyse MEDICAMEQ share price charts and track historical price performance.
Use the Medicamen Biotech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Medicamen Biotech Market Cap
₹320.76 Cr.
MEDICAMEQ P/E Ratio (TTM)
33.37
Medicamen Biotech P/B Ratio
1.19
EPS (TTM)
₹7.22
Dividend Yield
0.42%
Debt to Equity
0.15
MEDICAMEQ 52 Week High
₹415.95
Medicamen Biotech 52 Week Low
₹223.30
Operating Margin
9.00%
Profit Margin
6.45%
MEDICAMEQ Revenue (TTM)
₹62.00
EBITDA
₹7.00
Net Income
₹4.00
Total Assets
₹372.00
Total Equity
₹276.00
Medicamen Biotech Share Price Chart
Screen Medicamen Biotech share price with an interactive chart. Analyse MEDICAMEQ price trends and volatility across different timeframes.
Medicamen Biotech Company Profile - Fundamental Screener
Screen Medicamen Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for MEDICAMEQ shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE646B01010
Medicamen Biotech Balance Sheet Screener
Screen MEDICAMEQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 372 | 297 | 295 | 279 | 226 | 194 | 181 | 137 |
| Current Assets | 224 | 165 | 160 | 163 | 123 | 96 | 104 | 96 |
| Fixed Assets | 85 | 87 | 92 | 93 | 93 | 90 | 34 | 24 |
| Liabilities | ||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 9 | 6 | 3 | 3 | 7 | 8 | 4 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 276 | 213 | 207 | 193 | 147 | 133 | 121 | 87 |
| Share Capital | 14 | 13 | 13 | 13 | 12 | 12 | 12 | 12 |
| Reserves & Surplus | 262 | 200 | 194 | 178 | 134 | 121 | 109 | 75 |
Medicamen Biotech Income Statement Screener - Profit & Revenue Analysis
Screen Medicamen Biotech income statement and profit fundamentals.
Analyze MEDICAMEQ quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Medicamen Biotech share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62 | 47 | 48 | 44 | 35 | 48 | 44 | 45 | 45 | 39 | 42 | 44 | 47 | 23 | 34 |
| Expenses | 55 | 43 | 42 | 38 | 31 | 42 | 40 | 39 | 38 | 32 | 35 | 39 | 42 | 18 | 27 |
| EBITDA | 7 | 5 | 6 | 5 | 4 | 6 | 4 | 6 | 7 | 7 | 7 | 5 | 6 | 5 | 7 |
| Operating Profit % | 9.00% | 9.00% | 11.00% | 11.00% | -5.00% | 12.00% | 8.00% | 12.00% | 15.00% | 17.00% | 17.00% | 11.00% | 11.00% | 22.00% | 17.00% |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 5 | 2 | 3 | 2 | 3 | 3 | 2 | 2 | 4 | 4 | 5 | 3 | 3 | 3 | 4 |
| Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Profit | 4 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 3 | 4 | 4 | 2 | 2 | 3 | 4 |
| EPS | 3.28 | 1.21 | 1.56 | 1.18 | 1.47 | 1.61 | 0.63 | 0.71 | 2.30 | 3.03 | 3.12 | 1.17 | 1.60 | 2.25 | 2.94 |
Medicamen Biotech Cash Flow Screener - Liquidity Fundamentals
Screen MEDICAMEQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | -8 | -7 | -6 | 4 | 13 | 13 | 4 |
| Investing Activities | -1 | -6 | -6 | -9 | -18 | -37 | -15 |
| Financing Activities | -2 | 6 | 29 | 4 | 6 | 19 | -4 |
| Net Cash Flow | -11 | -6 | 17 | 0 | 1 | -5 | -14 |
Medicamen Biotech Shareholding Pattern Screener
See Medicamen Biotech shareholding pattern with promoter, FII, and DII holdings.
Check Medicamen Biotech promoter holding and ownership changes for MEDICAMEQ on TickJournal.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Apr | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 43.16% | 42.99% |
| FII Holding | 0.07% | 0.10% | 0.02% | 0.06% | 0.00% | 0.22% | 0.12% | 0.05% |
| DII Holding | 0.40% | 0.00% | 0.44% | 0.59% | 0.64% | 0.65% | 0.69% | 0.87% |
| Govt Holding | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.06% | 0.06% |
| Public Holding | 32.10% | 32.09% | 32.17% | 33.35% | 31.50% | 31.58% | 33.35% | 32.96% |
| Other Holding | 26.91% | 27.30% | 26.86% | 25.50% | 27.34% | 27.04% | 22.63% | 23.08% |
| Shareholder Count | 11,047 | 10,806 | 10,967 | 11,177 | 10,808 | 10,592 | 10,435 | 10,576 |
Medicamen Biotech Share Dividend Screener - Share Yield Analysis
Check Medicamen Biotech dividend history with payout and yield data.
View Medicamen Biotech dividend details including ex-dates and amounts for MEDICAMEQ stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.45% |
| 2024-March | ₹1.00 | 0.21% |
| 2023-March | ₹1.00 | 0.26% |
| 2022-March | ₹1.00 | 0.15% |
| 2021-March | ₹1.00 | 0.16% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Medicamen Biotech Stock Index Membership
See which indices include Medicamen Biotech stock.
Check MEDICAMEQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Medicamen Biotech Market Events Screener - Corporate Actions
Get Medicamen Biotech corporate actions including splits, bonuses, and buybacks.
Check Medicamen Biotech stock events that may affect MEDICAMEQ share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | 0.78% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | -6.83% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 7.40% |
| 2025-09-26 | 2025-09-26 | Annual General Meeting | NA | -9.63% |
| 2025-09-19 | 2025-09-19 | Dividend | ₹ 1.00 /share | -22.18% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -4.93% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.82% |
| 2025-03-26 | 2025-03-26 | Extraordinary General Meeting | NA | -16.66% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 6.85% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -14.31% |
| 2024-09-26 | 2024-09-26 | Annual General Meeting | NA | 20.69% |
| 2024-09-19 | 2024-09-19 | Dividend | ₹ 1.00 /share | -10.33% |
| 2023-09-20 | 2023-09-21 | Dividend | ₹ 1.00 /share | -6.07% |
| 2022-09-19 | 2022-09-21 | Dividend | ₹ 1.00 /share | 79.23% |
| 2021-09-16 | 2021-09-19 | Dividend | ₹ 1.00 /share | 14.55% |
Medicamen Biotech Competitors Screener - Peer Comparison
Screen MEDICAMEQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 469,406 | 40.30 | 61,674 | 12.69% | 11,565 | 67.08 |
| Divis Laboratories | 194,270 | 75.03 | 10,560 | 8.73% | 2,520 | 71.64 |
| Torrent Pharmaceuticals | 190,389 | 75.44 | 13,886 | 20.34% | 2,138 | 65.32 |
| Cipla | 116,459 | 29.67 | 29,045 | 2.24% | 3,870 | 55.65 |
| Zydus Life Science | 115,616 | 22.25 | 27,658 | 17.64% | 5,026 | 60.58 |
| Lupin | 113,325 | 20.85 | 29,039 | 26.75% | 5,356 | 59.41 |
| Mankind Pharma | 105,967 | 53.09 | 14,636 | 14.85% | 1,938 | 59.45 |
| Dr Reddys Laboratories | 102,088 | 24.31 | 35,059 | 3.90% | 4,158 | 35.59 |
| Aurobindo Pharma | 89,736 | 25.44 | 33,385 | 3.21% | 3,376 | 55.50 |
| Laurus Labs | 84,158 | 92.82 | 6,868 | 22.01% | 890 | 63.63 |
Medicamen Biotech Company Announcements - News Screener
Screen MEDICAMEQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-25 | Closure of Trading Window | - |
| 2026-05-28 | Corporate Action-Board to consider Dividend | - |
| 2026-05-28 | Compliances - Regulation 32 (1) And (3) - Statament Of Deviation & Variation Report - March 2026 | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-27 | Audited Stabdalone & Consolidated Financial Results For The Quarter And Year Ended On March 31 2026 | - |
| 2026-05-20 | Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated ) For The Quarter And Year Ended On March 31 2026 | - |
| 2026-04-16 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-06 | Announcement Under Regulation 30 (LODR) - Intimation Regarding Incorrect Event Disply On NSDL Portal | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-02-21 | Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-13 | Unaudited Financial Results For The Quarter Ended On December 31 2025 | - |
| 2026-02-04 | Board Meeting Intimation for Consideration Of Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-01-16 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-01-07 | Announcement Under Regulation 30 (LODR)- EU Approval For Product Registration Of Paracetamol | - |
| 2025-12-26 | Closure of Trading Window | - |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-14 | Financial Results For The Quarter And Half Year Ended On September 30 2025 | - |